ReviewClinical epidemiology2022
Identification of Biomarkers for Preeclampsia Based on Metabolomics.
Review in Clinical epidemiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Association between blood lipid levels and preeclampsia: a meta-analysis.Frontiers in medicine · 2026Pooled it
- Advances in pathogenesis of preeclampsia.Archives of gynecology and obstetrics · 2024Pooled it
- Investigating genetic links between blood metabolites and preeclampsia.BMC women's health · 2024Pooled it
- Development of a predictive model for preeclampsia utilizing time-of-flight mass spectrometry based on novel nanomaterials integrated with machine learning.BMC pregnancy and childbirth · 2026Article
- Single-cell and spatial transcriptomics identify SPP1 + trophoblast necroptosis as a potential contributor to late-onset preeclampsia via SPP1-CD44-mediated interaction with macrophages.Journal of translational medicine · 2026Article
- Amino acids: Missing link in preeclampsia pathogenesis?European journal of nutrition · 2026Observational
- First Trimester Triglyceride-Glucose Index and Lipid Profile as Predictive Factors in the Diagnosis of Late-Onset Preeclampsia: Can We Prevent It?Diagnostics (Basel, Switzerland) · 2025Article
- Metabolomic Profiles During and After a Hypertensive Disorder of Pregnancy: The EPOCH Study.International journal of molecular sciences · 2025Article
- Causal relationships between metabolic syndrome, plasma metabolites, and female reproductive diseases: insights from a two-step mendelian randomization approach.Nutrition & metabolism · 2025Article
- Glucose variability as a key mediator in the relationship between pre-pregnancy overweight/obesity and late-onset hypertensive disorders of pregnancy.Scientific reports · 2025Article
- Maternal-offspring brain and tissue cross-talk in preeclampsia: insights from a rat model.Metabolic brain disease · 2025Article
- Preeclampsia prediction and diagnosis: a comprehensive historical review from clinical insights to omics perspectives.Frontiers in medicine · 2025Review
- Circulating extracellular vesicular microRNA signatures in early gestation show an association with subsequent clinical features of pre-eclampsia.Scientific reports · 2024Article
- Clinical value of serum SIRT1 combined with uterine hemodynamics in predicting disease severity and fetal growth restriction in preeclampsia.Journal of medical biochemistry · 2024Article
- Metabolomic prediction of severe maternal and newborn complications in preeclampsia.Metabolomics : Official journal of the Metabolomic Society · 2024Article
- Maternal Acylcarnitine Disruption as a Potential Predictor of Preterm Birth in Primigravida: A Preliminary Investigation.Nutrients · 2024Article
- Statistical methods and resources for biomarker discovery using metabolomics.BMC bioinformatics · 2023Review
- Predictive Performance of Machine Learning-Based Methods for the Prediction of Preeclampsia-A Prospective Study.Journal of clinical medicine · 2023Article
- Clinical Value of Serum SIRT1 Combined with Uterine Hemodynamics in Predicting Disease Severity and Fetal Growth Restriction in Preeclampsia.Evidence-based complementary and alternative medicine : eCAM · 2023Article
- Targeted Metabolomics Revealed a Sex-Dependent Signature for Metabolic Syndrome in the Mexican Population.Nutrients · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Preeclampsia (PE) is a significant cause of maternal and neonatal morbidity and mortality worldwide. However, the pathogenesis of PE is unclear and reliable early diagnostic methods are still lacking. The purpose of this review is to summarize potential metabolic biomarkers and pathways of PE, which might facilitate risk prediction and clinical diagnosis, and obtain a better understanding of specific metabolic mechanisms of PE. Methods: This review included human metabolomics studies related to PE in the PubMed, Google Scholar, and Web of Science databases from January 2000 to November 2021. The reported metabolic biomarkers were systematically examined and compared. Pathway analysis was conducted through the online software MetaboAnalyst 5.0. Results: Forty-one human studies were included in this systematic review. Several metabolites, such as creatinine, glycine, L-isoleucine, and glucose and biomarkers with consistent trends (decanoylcarnitine, 3-hydroxyisovaleric acid, and octenoylcarnitine), were frequently reported. In addition, eight amino acid metabolism-related, three carbohydrate metabolism-related, one translation-related and one lipid metabolism-related pathways were identified. These biomarkers and pathways, closely related to renal dysfunction, insulin resistance, lipid metabolism disorder, activated inflammation, and impaired nitric oxide production, were very likely to contribute to the progression of PE. Conclusion: This study summarized several metabolites and metabolic pathways, which may be associated with PE. These high-frequency differential metabolites are promising to be biomarkers of PE for early diagnosis, and the prominent metabolic pathway may provide new insights for the understanding of the pathogenesis of PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.